BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.
Sidoti May 2024 Virtual Investor Conference
Format: Company Presentation
Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET
Location: Virtual
The Citizens JMP Life Sciences Conference
Format: Fireside Chat
Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET
Location: New York Hilton Midtown
Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcasts will be available for at least 30 days following the event.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, (formerly known as Twitter), and Instagram.
Investor Contacts:
Julie Rathbun
Athira Pharma
This email address is being protected from spambots. You need JavaScript enabled to view it.
206-769-9219
Anne Marie Fields
Stern Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
332-213-1956
Media Contact:
Janine Bogris
Inizio Evoke Comms
This email address is being protected from spambots. You need JavaScript enabled to view it.
201-245-6838
| Last Trade: | US$4.52 |
| Daily Volume: | 0 |
| Market Cap: | US$17.810M |
November 06, 2025 August 07, 2025 May 09, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
